An analyst sees Derma Sciences earning 50 cents a share on revenue of 140.9 million, including 14 million in sales from DSC127.
And should DSC127 fail at the FDA, the company will turn a profit 10 cents to 20 cents in 2016, on the strength of its wound-care business.
With their AWC business expected to grow +/- 40% annually, I believe this trend will continue for many more years to come. If they would not have the DSC 127 trial, they would probably be profitable by now. For 2013 analysts expect them to have net sales of 82.51 mio and for 2014 94.73 mio.
There is nothing to follow. Someone wanted to buy DSC127 some time ago but Quilty wanted to sell thw whole company.(that is what he does) Buyer only wanted DSC127 so no deal. Since then nothing has happened and with no trading it sits. Price can go up or down pretty high on low volume but it comes back to current level.